CLL
Conference Coverage
GLOW: Ibrutinib+venetoclax shines in first line for CLL/SLL
From the Journals
Patients with CLL have significantly reduced response to COVID-19 vaccine
Less than half of CLL patients had an antibody-mediated response to the Pfizer vaccine in a study.
Conference Coverage
Pediatric cancer survivors at risk for opioid misuse
From the Journals
GENUINE improvements: Ublituximab plus ibrutinib for CLL
From the Journals
CLL patients: Diagnostic difficulties, treatment confusion with COVID-19
Roundtables
New treatment approaches in CLL
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
From the Journals
New inhibitor shows promise in previously failed B-cell malignancies
Pirtobrutinib (formerly known as LOXO-305) is an oral-dose, highly selective, reversible inhibitor.
From the Journals
CLL, MBL had lower response rates to flu vaccination, compared with healthy adults
Patients with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis were assessed for their immune response.
Feature
Experts offer roadmap for treating CLL during the pandemic
Conference Coverage
Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies